Background: The purpose of this review was to provide a critical appraisal of the literature supporting the efficacy of ophthalmic ketorolac (Acuvail(®)) in the treatment of pain and inflammation after cataract surgery.
Methods: Literature search and expert opinion of the authors.
Results: Recent studies indicate greater intraocular drug levels in the anterior chamber and iris-ciliary body after topical application of Acuvail in comparison with older formulations of ketorolac. A large randomized, multicenter, placebo-controlled study demonstrated significantly less inflammation and pain after cataract surgery using Acuvail.
Conclusion: Acuvail appears to be effective in reducing post-cataract surgery pain and inflammation.
Keywords: Acuvail®; cystoid macular edema; ketorolac tromethamine; nonsteroidal anti-inflammatory drugs; postsurgical.